Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (90)	7/10/2002 6:02:29 PM
From: Hank	Read Replies (2) \| Respond to of 684

I don't have time to describe them "one by one". Suffice it to say that I spent 10 years of my career studying RNA viruses and I can tell you the best targets for drug development have all been thoroughly investigated. Most either center around inhibiting transcription by the corresponding RNA polymerase, proteolytic processing of precursor proteins, the inhibition of capsid degradation/formation, or the inhibition of virus binding to cell surface receptors. If you want to know the details of these processes for each virus I suggest to go to your local medical school library and look at a Virology text. By the way, if you think that is a lot targets, then you ought to look into the field of oncology/signal transduction. Viral processes are relatively simple compared to what goes on inside a tumor cell. You can clone an entire viral genome to genetically engineer an "infectious" DNA vector because for most viruses scientists know what very single gene does and how it helps the virus to replicate. Just try doing that for a tumor cell. As for Wyeth's involvement, I know the players and have a pretty good idea of how that came about but I'm not about to comment on it here.